Inactive Instrument

News Peregrine Pharmaceuticals Nasdaq

Equities

US7136613046

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Avid Bioservices: Fiscal Q3 Earnings Snapshot	Apr. 24	AQ
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024	Apr. 24	AQ
Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Apr. 24	CI
North American Morning Briefing : Stock Futures -2-	Apr. 19	DJ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO	Apr. 12	PR
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO	Apr. 04	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO	Mar. 27	PR
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Avid Bioservices Receives Nasdaq Noncompliance Notice	Mar. 20	MT
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q	Mar. 20	AQ
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	Mar. 15	DJ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors	Mar. 14	BU
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 14	BU
Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors	Mar. 13	BU
The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors	Mar. 13	BU
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating	Mar. 11	MT
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 07	BU
Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump	Mar. 07	MT
CDMO LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation – CDMO	Mar. 07	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Peregrine Pharmaceuticals Nasdaq

Equities

US7136613046

Summary

Filters